🏛️ Verified NIH Record • Updated 2026-06-03
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma (NCT03918252)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🩺 Plain-English Summary (8th-Grade Level)
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
Who can join: Review the eligibility criteria below.
Location: Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine — Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland
- University of Texas M.D. Anderson Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mesothelioma
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors — Los Angeles, California
- Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma — Tampa, Florida
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer — San Francisco, California
- Olaparib in Patients With HRD Malignant Mesothelioma — Chicago, Illinois
- A Study of Sacituzumab Govitecan in People With Mesothelioma — Basking Ridge, New Jersey
Explore by condition: All Mesothelioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.